Enveric Biosciences Reports Fourth Quarter and Year-End 2022 Corporate and Financial Results

Key HighlightsNominated EB-373 as lead development candidate for the treatment of anxiety disordersEB-373 is a next generation proprietary psilocin prodrug selected from Enveric’s EVM201 Series and developed leveraging the Company’s Psybrary™ drug discovery platformEstablished Australia-based subsidiary, Enveric The...

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Australia ,Australian ,Enveric Biosciences ,Casey Mcdonald ,Kevin Coveney ,Joseph Tucker ,Daniel Kontoh Boateng ,Akos Biosciences Inc ,Therapeutic Goods Administration ,Nasdaq ,Acanna Therapeutics Inc ,Tiberend Strategic Advisors Inc ,Company Psybrary ,Enveric Biosciences Inc ,International Neurology ,Exchange Commission ,Enveric Therapeutics ,Avance Clinical ,Chief Financial Officer ,Lynn Gallant ,Vice President ,Akos Biosciences ,Brain Disorders Conference ,Pipeline Targeting Unmet Needs ,Leading Developer ,Novel Small Molecule Therapeutics ,Acanna Therapeutics ,Intellectual Property ,New Chemical Entities ,Annual Report ,Quarterly Reports ,Strategic Advisors ,